Emergent Biosolutions teams with Asimov to advance antibody candidate pipeline

Emergent Biosolutions teams with Asimov to advance antibody candidate pipeline
Emergent Biosolutions, Asimov in partnership

Emergent Biosolutions announced a new partnership with Asimov to accelerate the development of innovative antibody candidates aimed at strengthening preparedness against evolving biological threats.

The collaboration is focused on driving progress in novel antibody research to enhance protection measures and support public health defense initiatives.

Emergent Biosolutions recently secured up to a $22.3 million contract modification with the U.S. Department of War to supply medical products, according to a previous company announcement. The contract is part of the firm's ongoing efforts to support government preparedness initiatives. The new partnership with Asimov builds on these activities by advancing antibody research aimed at countering biological risks.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.